Health
FDA Approves Dostarlimab for dMMR Rectal Cancer, an Option That May Spare Some Patients Surgery
The first immunotherapy cleared for locally advanced rectal cancer with a specific tumour fingerprint, approved four months early on interim data that still needs confirming.
Oct 19, 2026
